Background. Myocarditis is a severe cardiovascular complication of influenza infection that is often fatal and underdiagnosed. We evaluated the epidemiology of influenza myocarditis (IM) among inpatients at one institution.
Methods. We performed a retrospective cohort study of inpatients harboring influenza virus by reverse transcription-polymerase chain reaction from respiratory specimens between 2014 and 2016. We collected demographic, treatment, strain-typing, and hospitalization data for all patients. Definitive IM was proven by histopathology or viral isolation from myocardial tissue. Probable and possible IM were based on CDC and predefined clinical criteria, respectively. We used the chi-squared test to compare characteristics between 2014-2015 and 2015-2016 influenza seasons and the subset of patients with cardiovascular complications.
Results. We identified 757 patients with influenza in 2014-2015 (n = 453) and 2015-2016 (n = 304) . Baseline characteristics including gender, influenza type, and co-morbidities were similar between seasons except for more white and cardiovascular disease (P <0.005) in 2014-2015. Overall, five (0.7%) (2014-2015 = 4, 2015-2016 = 1) had probable IM. Median age was 65 years (range 29-87) and median length of stay was 4 days (range 4-15). All had EKG changes, one had increased heart size without effusion requiring ICU stay and intubation. Four received oseltamivir, and all survived.
Possible IM occurred in 39 patients (5%) based on new EKG changes (58%), troponin elevation (38%) and pericardial effusion (2%). These patients were older (median 81 years, range 29-91) with longer length-of-stay (median 8 days, range 1-41). Oseltamivir was given to 30/39 (77%). Death occurred in 5/23 patients with EKG changes and 3/15 with troponin elevation.
Conclusion. IM was rare during the past two influenza seasons with no attributable mortality at our institution. Eight-fold more patients with IM were detected using a priori criteria when compared with CDC criteria with substantially higher mortality. This may represent a high-risk subset for whom future studies are needed to improve IM diagnosis and prevent morbidity and mortality.
Disclosures. All authors: No reported disclosures. Background. Vaccination and treatment with neuraminidase inhibitors can reduce incidence and severity of influenza. Observational studies suggest antiviral treatment reduces influenza symptom duration and severe outcomes among hospitalized patients. The interaction of the effects of vaccination and antiviral treatment against severe influenza has not been established.
Influenza Vaccination and Treatment with Antiviral Agents Among
Methods. We used data from a test-negative influenza vaccine effectiveness study. The parent study enrolled adults admitted to two hospitals in Michigan with an acute respiratory illness of ≤10 days duration during the 2014-2015 and 2015-2016 influenza seasons. Respiratory swabs from enrolled patients were tested for influenza by RT-PCR; influenza-positive individuals were included in this analysis. We evaluated predictors of vaccination and antiviral treatment using logistic regression. We also assessed the association between antiviral treatment and hospital length of stay (LOS) using linear regression models stratified by vaccination status.
Results. We included 200 individuals in the analysis; 103 (51.5%) were vaccinated and 135 (67.5%) were treated with antivirals. Significant predictors of vaccination included age ≥65, white race, a Charlson comorbidity index (CCI) score ≥3, study site, and increased past-year health care visits. Antiviral treatment varied by study site and was more common in the 2015-2016 season and among those aged 18-49. Vaccination was not associated with antiviral treatment or with time from illness onset to treatment. Antiviral treatment was associated with reduced LOS (percent change in LOS: −23.6% (−39.2%, −4.1%), P = 0.02) among vaccinated participants but not among unvaccinated participants (21.1% (−10.9%, 64.8%), P = 0.22) after adjustment for sex, age, influenza subtype, site, CCI, frailty, and past-year health care contacts. When an interaction term was used in lieu of stratification the interaction was significant (P = 0.01). This difference in antiviral effectiveness by vaccination status held across age groups, but was most dramatic for those aged 18-49.
Conclusion. Vaccinated individuals were more likely than unvaccinated individuals to benefit from antiviral treatment. This finding warrants confirmation in other populations. 
